Early Alzheimer’s Detection

Science & Technology Science

Posted by NewAdmin on 2025-02-11 08:47:41 |

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 10

---

Early detection of Alzheimer’s disease is crucial for effective intervention, and recent advancements have made promising progress in this area. Researchers have developed a blood test that can detect toxic amyloid-beta (Aβ) oligomers—small protein aggregates that contribute to Alzheimer’s disease—long before symptoms appear. These toxic proteins start forming over a decade before cognitive decline becomes evident, making early detection critical.

A research team funded by the National Institutes of Health (NIH) developed the Soluble Oligomer Binding Assay (SOBA), which detects Aβ oligomers in blood samples. The method relies on synthetic molecules that specifically bind to the toxic oligomers, distinguishing them from harmless protein forms. In testing, SOBA identified Aβ oligomers in nearly all Alzheimer’s patients and even detected the proteins in some cognitively healthy individuals who later developed mild cognitive impairment. This suggests the test could predict Alzheimer’s years before traditional symptoms appear.

Beyond Alzheimer’s, SOBA has potential applications for detecting other neurodegenerative diseases like Parkinson’s and Lewy body dementia, as these conditions also involve toxic protein oligomers. Researchers believe this method could not only help with early diagnosis but also serve as a tool for tracking disease progression and evaluating treatment efficacy. If widely adopted, blood tests like SOBA could revolutionize Alzheimer’s diagnostics, leading to earlier interventions and potentially slowing disease progression before significant brain damage occurs.

Go!